Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
<p>Pharmacokinetic analysis of merestinib and LY2874455. A, Merestinib plasma levels were measured at the time points shown and compared between patients receiving single-agent merestinib in Cohort 1 (n=7, black line) and patients receiving merestinib + LY2874455 in Cohort 2 (n=8, red line). G...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , , , , , , , , , , , , , , , , |
| Veröffentlicht: |
2025
|
| Schlagworte: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1849927633693835264 |
|---|---|
| author | Evan C. Chen (15054014) |
| author2 | Helen Gandler (15054017) Isidora Tošić (15054020) Geoffrey G. Fell (15054023) Ashlee Fiore (15054026) Olga Pozdnyakova (15054029) Daniel J. DeAngelo (15031959) Ilene Galinsky (15054032) Marlise R. Luskin (15054035) Martha Wadleigh (15054038) Eric S. Winer (15054041) Rebecca Leonard (15054044) Kelsey O'Day (15054047) Adrienne de Jonge (15054050) Donna Neuberg (15038318) A. Thomas Look (14951403) Richard M. Stone (15054053) David A. Frank (14961075) Jacqueline S. Garcia (15043140) |
| author2_role | author author author author author author author author author author author author author author author author author author |
| author_facet | Evan C. Chen (15054014) Helen Gandler (15054017) Isidora Tošić (15054020) Geoffrey G. Fell (15054023) Ashlee Fiore (15054026) Olga Pozdnyakova (15054029) Daniel J. DeAngelo (15031959) Ilene Galinsky (15054032) Marlise R. Luskin (15054035) Martha Wadleigh (15054038) Eric S. Winer (15054041) Rebecca Leonard (15054044) Kelsey O'Day (15054047) Adrienne de Jonge (15054050) Donna Neuberg (15038318) A. Thomas Look (14951403) Richard M. Stone (15054053) David A. Frank (14961075) Jacqueline S. Garcia (15043140) |
| author_role | author |
| dc.creator.none.fl_str_mv | Evan C. Chen (15054014) Helen Gandler (15054017) Isidora Tošić (15054020) Geoffrey G. Fell (15054023) Ashlee Fiore (15054026) Olga Pozdnyakova (15054029) Daniel J. DeAngelo (15031959) Ilene Galinsky (15054032) Marlise R. Luskin (15054035) Martha Wadleigh (15054038) Eric S. Winer (15054041) Rebecca Leonard (15054044) Kelsey O'Day (15054047) Adrienne de Jonge (15054050) Donna Neuberg (15038318) A. Thomas Look (14951403) Richard M. Stone (15054053) David A. Frank (14961075) Jacqueline S. Garcia (15043140) |
| dc.date.none.fl_str_mv | 2025-11-25T13:01:52Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30706823 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_S5_from_Targeting_MET_and_FGFR_in_Relapsed_or_Refractory_Acute_Myeloid_Leukemia_Preclinical_and_Clinical_Findings_and_Signal_Transduction_Correlates/30706823 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Leukemias Pharmacology Pharmacokinetics and pharmacodynamics Precision Medicine Small Molecule Agents Kinase inhibitors Translational Research |
| dc.title.none.fl_str_mv | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Pharmacokinetic analysis of merestinib and LY2874455. A, Merestinib plasma levels were measured at the time points shown and compared between patients receiving single-agent merestinib in Cohort 1 (n=7, black line) and patients receiving merestinib + LY2874455 in Cohort 2 (n=8, red line). Geometric mean is displayed. Error bars denote standard error. * signifies p < 0.05. B, Plasma levels of merestinib (first column) and its metabolites LSN2800870 and LSN2887652 (second and third columns, respectively) in patients receiving merestinib monotherapy (first row) and merestinib + LY2874455 (second row). C, Plasma levels of LY2874455 in patients receiving merestinib + LY2874455. Abbreviations: Cohort 1 = patients receiving single-agent merestinib; Cohort 2 = patients receiving merestinib + LY2874455.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_e9c3822a995daaac70da25c702639d16 |
| identifier_str_mv | 10.1158/1078-0432.30706823 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30706823 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction CorrelatesEvan C. Chen (15054014)Helen Gandler (15054017)Isidora Tošić (15054020)Geoffrey G. Fell (15054023)Ashlee Fiore (15054026)Olga Pozdnyakova (15054029)Daniel J. DeAngelo (15031959)Ilene Galinsky (15054032)Marlise R. Luskin (15054035)Martha Wadleigh (15054038)Eric S. Winer (15054041)Rebecca Leonard (15054044)Kelsey O'Day (15054047)Adrienne de Jonge (15054050)Donna Neuberg (15038318)A. Thomas Look (14951403)Richard M. Stone (15054053)David A. Frank (14961075)Jacqueline S. Garcia (15043140)CancerTherapeutic Research and DevelopmentClinical Research and TrialsClinical Trial ResultsPhase I clinical trialsDrug TargetsProtein kinase & phosphatase drug targetsHematological CancersLeukemiasPharmacologyPharmacokinetics and pharmacodynamicsPrecision MedicineSmall Molecule AgentsKinase inhibitorsTranslational Research<p>Pharmacokinetic analysis of merestinib and LY2874455. A, Merestinib plasma levels were measured at the time points shown and compared between patients receiving single-agent merestinib in Cohort 1 (n=7, black line) and patients receiving merestinib + LY2874455 in Cohort 2 (n=8, red line). Geometric mean is displayed. Error bars denote standard error. * signifies p < 0.05. B, Plasma levels of merestinib (first column) and its metabolites LSN2800870 and LSN2887652 (second and third columns, respectively) in patients receiving merestinib monotherapy (first row) and merestinib + LY2874455 (second row). C, Plasma levels of LY2874455 in patients receiving merestinib + LY2874455. Abbreviations: Cohort 1 = patients receiving single-agent merestinib; Cohort 2 = patients receiving merestinib + LY2874455.</p>2025-11-25T13:01:52ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706823https://figshare.com/articles/figure/Figure_S5_from_Targeting_MET_and_FGFR_in_Relapsed_or_Refractory_Acute_Myeloid_Leukemia_Preclinical_and_Clinical_Findings_and_Signal_Transduction_Correlates/30706823CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307068232025-11-25T13:01:52Z |
| spellingShingle | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Evan C. Chen (15054014) Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Leukemias Pharmacology Pharmacokinetics and pharmacodynamics Precision Medicine Small Molecule Agents Kinase inhibitors Translational Research |
| status_str | publishedVersion |
| title | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_full | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_fullStr | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_full_unstemmed | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_short | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| title_sort | Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates |
| topic | Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Leukemias Pharmacology Pharmacokinetics and pharmacodynamics Precision Medicine Small Molecule Agents Kinase inhibitors Translational Research |